

CONCERT PHARMACEUTICALS, INC.

Form 8-K

April 10, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): April 8, 2015**

**Concert Pharmaceuticals, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**001-36310**  
**(Commission**

**File Number)**

**20-4839882**  
**(IRS Employer**

**Identification No.)**

**99 Hayden Avenue, Suite 500**

**Lexington, Massachusetts**  
**(Address of Principal Executive Offices)**

**02421**  
**(Zip Code)**

**Registrant's telephone number, including area code: (781) 860-0045**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On April 8, 2015, Dr. John G. Freund, a member of the Board of Directors (the Board ) of Concert Pharmaceuticals, Inc., (the Company ) informed the Company of his decision to resign from the Board effective as of June 11, 2015. Dr. Freund's decision to resign was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CONCERT PHARMACEUTICALS, INC.

By: /s/ Roger D. Tung  
Roger D. Tung

Date: April 10, 2015